# Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

> **NCT02306850** · PHASE2 · COMPLETED · sponsor: **St. Louis University** · enrollment: 10 (actual)

## Conditions studied

- Unresectable Malignant Neoplasm
- Melanoma
- Metastatic Melanoma
- Stage IV Melanoma
- Stage III Melanoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02306850
- **Lead sponsor:** St. Louis University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-06-08
- **Final completion:** 2018-06-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02306850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02306850, "Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02306850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*